Visitprime
A patient-consented pre-visit preparation flow that captures symptoms, context, medications to review, and questions, then routes an exact source-labeled draft to staff before any record write.
Enterprise patient-intake platforms validate the pre-visit workflow, and the supplied research found no mid-market-native product at the proposed positioning. Visitprime sends an approved reminder 24 to 72 hours before a scheduled encounter, verifies the intended patient or proxy, obtains consent, and offers an accessible structured flow for the patient's own words, symptom timing and context, medications the patient wants reviewed, and questions for the clinician. It does not diagnose, triage, generate a review of systems as clinical fact, reconcile medication authoritatively, determine urgency, recommend care, choose billing, or delay emergency help. The output is visibly labeled patient-supplied and unverified. Staff review, edit, reject, and decide whether the exact version is attached to the encounter through a verified clinical interface. The source confirms public developer portals and health-data standards, but the original stage verified no production API for the target workflow; registration, scopes, patient matching, write authority, provenance, destination readback, and correction remain gates. Security agreements, privacy controls, regulated-product analysis, and clinical validation are external requirements.
The ambulatory operations, patient-access, clinical informatics, digital health, or practice leader at a mid-market health system or specialty group.
Consumer preparation interest and enterprise pricing gaps support current testing without a deadline.
Health-system and specialty-group operators are identified, while exact size, owner, budget, and workflow remain broad.
Three cross-references and four inbound connections support the pre-visit and mid-market integration family.
Enterprise workflow validation, public developer portals, a clear mid-market buyer hypothesis, and no direct product found support a focused preparation layer.
Production access was not verified, patient identity and consent are hard, clinical and regulated-product risk is substantial, EHR writeback is fragmented, the price gap relies on estimates, and incumbents can move down-market.
Discussion
No comments yet — be the first to weigh in.